Oragenics' concussion drug ONP-002 passes FDA cardiotoxicity test, Phase II planned

ORAGENICS INC

ONP-002 showed no cardiotoxicity in GLP hERG study conducted by Charles River Laboratories.
Inhibitory concentration >10 µM; large cardiac safety margin based on Phase I plasma levels.
Phase II trial planning underway to evaluate ONP-002 in concussed patients.
Concussion market estimated at 69M cases globally; annual US healthcare cost for TBIs exceeds $40.6B.
ONP-002 is an intranasal neurosteroid new chemical entity targeting mild traumatic brain injury.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.